A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment
Study sponsor: PepGen Inc · PEPG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-28Actual
Enrollment · participants7Actual
Source updated2025-12-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.